GENOR BIOPHARMA DL-00002 Financial Flexibility Index
GENOR BIOPHARMA DL-00002 financial flexibility index. GENOR BIOPHARMA DL-00002 (67N0) has a Financial Flexibility Index of -0.87x as of December 2024. Free cash flow of €-120.41 Million (operating CF €-121.98 Million minus capex €1.57 Million) represents -1% of total liabilities (€138.05 Million).
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of GENOR BIOPHARMA DL-00002 (2021–2024)
Financial flexibility index of GENOR BIOPHARMA DL-00002 from 2021 to 2024. Historical Financial Flexibility Index trend for GENOR BIOPHARMA DL-00002 across 4 annual periods. Explore 67N0 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
GENOR BIOPHARMA DL-00002 Financial Flexibility Index by Year (2021–2024)
GENOR BIOPHARMA DL-00002 financial flexibility index by year from 2021 to 2024. Year-by-year free cash flow to debt coverage for GENOR BIOPHARMA DL-00002. For the full cash flow conversion analysis, see cash flow conversion of GENOR BIOPHARMA DL-00002.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -0.87x | €-120.41 Million | €-121.98 Million | €138.05 Million | ▲ +47.3% |
| 2023 | -1.66x | €-424.09 Million | €-425.12 Million | €256.18 Million | ▲ +9.2% |
| 2022 | -1.82x | €-564.65 Million | €-577.61 Million | €309.87 Million | ▼ -22.0% |
| 2021 | -1.49x | €-552.35 Million | €-623.74 Million | €369.73 Million | — |